-
公开(公告)号：US10258625B2
公开(公告)日：2019-04-16
申请号：US15661100
申请日：2017-07-27
IPC分类号： A61K38/20 , A61K38/17 , A61K31/166 , A61K31/18 , A61K8/49 , A61K31/277 , A61P35/00 , A61P35/04 , A61K31/519 , A61K31/4184 , A61K31/4458 , A61K31/437 , A61K31/145 , A61K31/397 , A61K31/506 , A61K9/19 , A61K45/06 , A61K31/4523 , A61K31/4709 , C12N9/12 , C07K14/54 , C07D471/04 , C07K14/715
摘要： A method of treating a mammalian subject with cancer comprises administering to said subject having a cancer, e.g., a metastatic or refractory cancer or tumor, a small molecule inhibitor of a target signaling molecule of the MEK/MAPK pathway that impairs T cell activation, and administering to said subject a molecule that induces T cell proliferation in the presence of said inhibitor. The combination of a small molecule inhibitor of a target of the MEK/MAPK pathway and the T cell proliferation inducer reduces the proliferation of the cancer and tumor cells in vivo. Compositions and kits including these components are also provided.
-
2.发明申请公开(公告)号：US20170326205A1
公开(公告)日：2017-11-16
申请号：US15661100
申请日：2017-07-27
IPC分类号： A61K38/20 , A61K31/4184 , A61K9/19 , A61K31/277 , A61K31/519
CPC分类号： A61K31/519 , A61K8/4946 , A61K9/19 , A61K31/145 , A61K31/166 , A61K31/18 , A61K31/277 , A61K31/397 , A61K31/4184 , A61K31/437 , A61K31/4458 , A61K31/4523 , A61K31/4709 , A61K31/506 , A61K38/1793 , A61K38/2013 , A61K38/2046 , A61K38/2086 , A61K45/06 , A61K2300/00 , A61P35/04 , C07D471/04 , C07K14/5418 , C07K14/5443 , C07K14/7155 , C12N9/12 , C12Y207/11024
摘要： A method of treating a mammalian subject with cancer comprises administering to said subject having a cancer, e.g., a metastatic or refractory cancer or tumor, a small molecule inhibitor of a target signaling molecule of the MEK/MAPK pathway that impairs T cell activation, and administering to said subject a molecule that induces T cell proliferation in the presence of said inhibitor. The combination of a small molecule inhibitor of a target of the MEK/MAPK pathway and the T cell proliferation inducer reduces the proliferation of the cancer and tumor cells in vivo. Compositions and kits including these components are also provided.
-
3.发明申请公开(公告)号：US20170020964A1
公开(公告)日：2017-01-26
申请号：US15285854
申请日：2016-10-05
IPC分类号： A61K38/20 , A61K31/145 , A61K31/4458 , A61K31/437 , A61K31/519 , A61K31/4184
CPC分类号： A61K38/2086 , A61K9/19 , A61K31/145 , A61K31/18 , A61K31/277 , A61K31/397 , A61K31/4184 , A61K31/437 , A61K31/4458 , A61K31/4523 , A61K31/4709 , A61K31/506 , A61K31/519 , A61K38/1793 , A61K38/2013 , A61K38/2046 , A61K45/06 , A61P35/04 , C07D471/04 , C07K14/5418 , C07K14/5443 , C07K14/7155 , C12N9/12 , C12Y207/11024 , A61K2300/00
摘要： A method of treating a mammalian subject with cancer comprises administering to said subject having a cancer, e.g., a metastatic or refractory cancer or tumor, a small molecule inhibitor of a target signaling molecule of the MEK/MAPK pathway that impairs T cell activation, and administering to said subject a molecule that induces T cell proliferation in the presence of said inhibitor. The combination of a small molecule inhibitor of a target of the MEK/MAPK pathway and the T cell proliferation inducer reduces the proliferation of the cancer and tumor cells in vivo. Compositions and kits including these components are also provided.
摘要翻译： 用癌症治疗哺乳动物受试者的方法包括对所述患有癌症的受试者（例如转移性或难治性癌症或肿瘤）给予MEK / MAPK途径的靶信号分子的小分子抑制剂，其损害T细胞活化，以及 向所述受试者施用在所述抑制剂存在下诱导T细胞增殖的分子。 MEK / MAPK通路靶标的小分子抑制剂与T细胞增殖诱导剂的结合减少了体内癌细胞和肿瘤细胞的增殖。 还提供了包括这些组分的组合物和试剂盒。
-
公开(公告)号：US09724393B2
公开(公告)日：2017-08-08
申请号：US15285854
申请日：2016-10-05
IPC分类号： A61P35/00 , A61P35/04 , A61K38/20 , A61K38/17 , A61K31/519 , A61K31/506 , A61K31/397 , A61K31/4184 , A61K31/4458 , A61K31/437 , A61K31/145 , C07K14/54 , C07K14/715 , C07D471/04
CPC分类号： A61K38/2086 , A61K9/19 , A61K31/145 , A61K31/18 , A61K31/277 , A61K31/397 , A61K31/4184 , A61K31/437 , A61K31/4458 , A61K31/4523 , A61K31/4709 , A61K31/506 , A61K31/519 , A61K38/1793 , A61K38/2013 , A61K38/2046 , A61K45/06 , A61P35/04 , C07D471/04 , C07K14/5418 , C07K14/5443 , C07K14/7155 , C12N9/12 , C12Y207/11024 , A61K2300/00
摘要： A method of treating a mammalian subject with cancer comprises administering to said subject having a cancer, e.g., a metastatic or refractory cancer or tumor, a small molecule inhibitor of a target signaling molecule of the MEK/MAPK pathway that impairs T cell activation, and administering to said subject a molecule that induces T cell proliferation in the presence of said inhibitor. The combination of a small molecule inhibitor of a target of the MEK/MAPK pathway and the T cell proliferation inducer reduces the proliferation of the cancer and tumor cells in vivo. Compositions and kits including these components are also provided.
-
5.发明申请公开(公告)号：US20180280393A1
公开(公告)日：2018-10-04
申请号：US15765845
申请日：2016-10-05
IPC分类号： A61K31/519 , A61K31/4709 , A61K31/4523 , A61K31/437 , A61K31/4184 , A61K31/277 , A61K31/145 , A61P35/04
摘要： A method of treating a mammalian subject with cancer comprises administering to said subject having a cancer, e.g., a metastatic or refractory cancer or tumor, a small molecule inhibitor of a target signaling molecule of the MEK/MAPK pathway that impairs T cell activation, and administering to said subject a molecule that induces T cell proliferation in the presence of said inhibitor. The combination of a small molecule inhibitor of a target of the MEK/MAPK pathway and the T cell proliferation inducer reduces the proliferation of the cancer and tumor cells in vivo. Compositions and kits including these components are also provided.
-
-
-
-
搜索结果
5 条记录 (耗时 0.018 秒)
